Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of Open Label Study With Multiple (and for Non Responders) Escalating Subcutaneous Doses of BI 655064 Once a Week in Patients With Chronic Primary Immune Thrombocytopenic Purpura.
Inclusion and Exclusion Criteria
- Male and female chronic immune ITP patients
- Any treatment of ITP excluded except for a stable dose of corticosteroids (up to 20 mg)
Please contact Maria Brown to learn more about where you can participate in this trial. Please use the contact form on the right side.